MIER family member 2Genealiases: KIAA1193 · Mi-er2
Q-omics provides the consensus-scored MIER2 profile across patient tissues and cancer cell-line models. MIER2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MIER2 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, MIER2 RNA expression shows 18,513 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, COAD, and ACC as cancer lineages where MIER2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIER2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIER2 survival associations across molecular data types. MIER2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIER2 RNA expression–survival associations across cancer types. High MIER2 expression shows unfavorable associations in MESO, ACC, COAD, KIRP and LGG, but favorable associations in SCLC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MIER2 RNA expression.
This table summarizes MIER2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MIER2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIER2 shows lower tumor expression in KICH and higher tumor expression in COAD, HNSC, KIRC, LIHC and READ. The COAD box plot shows higher MIER2 RNA expression in tumor versus normal tissue (log2 FC = +1.046, t-test p < 0.001).
This table shows molecular features associated with MIER2 in patient tissues and cancer cell lines. In patient samples, MIER2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MIER2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
